RELAPSED AND REFRACTORY MM WITH HIGH RISK CYTOGENETICS

Is SARCLISA + Pd appropriate for your RRMM patients?

Meet John — A patient with relapsed and refractory MM with high risk cytogenetics* and disease progression after 3L treatment

Age
74 years old
Gender
Male
Time since MM diagnosis
3 years
R-ISS stage at diagnosis
Stage III
Additional medical history
Hypertension

Initial treatment

  • John was ineligible for ASCT and treatment was initiated with the cyclophosphamide, thalidomide, dexamethasone (CTd) regimen
  • Cytogenetic analysis showed translocation t(4:14)

Disease progression

  • John’s disease progressed after 1.5 years
  • John received second-line treatment with the bortezomib, dexamethasone (Vd) regimen and achieved a VGPR
  • One year later, John was diagnosed with disease progression after a regular follow-up with his doctor and received ixazomib, lenalidomide, dexamethasone (IxaRd) and achieved a partial response (PR)
  • John had disease progression while on therapy with IxaRd

Additional patient information

Cytogenetic risk
High
Bone marrow plasma cells
40%
Hg
11 g/dL
Multiple bone lesions
Beta-2 microglobulin
4.0 µL/mL
Renal function (CrCl)
80 mL/min/1.73 m2
Would John be a candidate for treatment with SARCLISA + Pd?

John would be eligible for treatment with SARCLISA + Pd1,2

Percentage of patients receiving SARCLISA + Pd in the ICARIA-MM trial with similar baseline characteristics2

You are now leaving the https://sarclisa.co.uk website.

By clicking on this link, you will be leaving this Sanofi hosted website, and, depending on the link, will be redirected to either another Sanofi website (for example, to view the Sanofi Privacy Policy) or an independent third-party website.
Sanofi has no control over the content or availability of third-party sites or resources that are linked to, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. The existence of a link between this website and any third party site or resource in no way implies that Sanofi in any way approves of the content of these sites or resources, or any use to which such content maybe put.

Please ensure that you read the legal and privacy policy sections of any website to which you link.

CONTINUE